Transparency, Please! MBTA Resists Disclosure of Arbitration Award

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Joe Selvaggi talks with attorney for Pioneer Public Interest Law Center (PPILC) John La Liberte, about the work he did to successfully gain access to the MBTA retirement fund’s arbitration agreement after a seven-month legal struggle.

Guest:

John La Liberte has been a litigator at a prestigious Boston boutique firm for over 30 years where he has also served as the firm’s general counsel. John
decided that he wanted to join Pioneer Public Interest Law Center to do what he hoped to do when he went to law school — engage in impact litigation.
WATCH:

Recent Episodes

Landlord’s Foreseeable Duty: Who Is Liable When Crime Lands on the Doorstep?

Joe Selvaggi talks with retired Federal Judge Frank Bailey, president of Pioneer Public Interest Law Center, about the Massachusetts Supreme Judicial Court's decision in Hill-Junious v. UTP Realty, LLC, regarding the limits of liability for a landlord when a murder occurs near her tenant’s location, and the challenges facing small entrepreneurs in high-crime communities.

Trump’s Trial’s Tribulations: Legal Merits of Four Federal Felony Fraud Indictments

Joe Selvaggi talks with legal scholar and George Mason University professor Ilya Somin about the legal merits of the federal indictments against former President Donald Trump and what is likely to come next in the legal proceedings against him and other defendants in the cases involving the aftermath of the 2020 presidential election.

Black Box Budget: Late, Loaded, and Lacking Transparency

Joe Selvaggi talks with Pioneer Institute’s Senior Fellow in Economic Opportunity Eileen McAnneny about the features and flaws of the recently passed 2024 Massachusetts state budget now waiting for Governor Healey’s approval.

Sabotaging Strategic Success: How Price Controls Could Imperil U.S. Pharma Industry

Joe Selvaggi talks with Pioneer Institute’s Director of Life Sciences Initiative Dr. Bill Smith about the policies that drove biopharmaceutical company from Europe to the U.S., and how proposed, similar price controls in President Biden’s Fair Prices Act could distort incentives away from innovation and threaten the success of a thriving and vital U.S. industry.